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ALK2Fibrodysplasia ossiﬁcans progressiva, an ultra-rare and disabling genetic disorder of skeletal malformations and
progressive heterotopic ossiﬁcation (HO), is the most catastrophic condition of skeletal metamorphosis in
humans. We studied 72 patients with FOP in China and analyzed their phenotypes and genotypes comprising
the world's largest ethnically homogeneous population of FOP patients. Ninety-nine percent of patients (71/72
cases) were of Han nationality; and 1% of patients (1/72 cases) were of Hui nationality. Based on clinical exam-
ination, 92% of patients (66/72 cases) had classic FOP; 4% of patients (3/72 cases) were FOP-plus; and 4% of pa-
tients (3/72) were FOP variants. Importantly, all individuals with FOP had mutations in the protein-coding
region of activin A receptor, type I/activin-like kinase 2 (ACVR1/ALK2). Ninety-seven percent of FOP patients
(70/72 cases) had the canonical c.617GNA (p.R206H)mutation, while 3% of FOP patients (2/72 cases) had variant
mutations in ACVR1/ALK2. Taken together, the genotypes and phenotypes of individuals with FOP from the Han
nationality in China are similar to those reported elsewhere and support the ﬁdelity of this ultra-rare disorder in
the world's most highly populated nation and across wide racial, ethnic, gender and geographic distributions.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Fibrodysplasia ossiﬁcans progressiva (FOP; MIM #135100) is an
ultra-rare disorder characterized by malformations of the great toes
and progressive extra-skeletal ossiﬁcations that form a disabling second
skeleton of heterotopic bone [1,2]. In FOP, heterotopic ossiﬁcation (HO)
is episodic and results from ﬂare-ups that occur spontaneously or sec-
ondary to trauma; disability is cumulative [1]. Progression of FOP lesions
occurs in speciﬁc anatomic patterns [3]. Due to the rarity of FOP, most
patients are misdiagnosed [4]. The mean age of death is 40 years,
most commonly from respiratory insufﬁciency due to severe restrictive
disease of the chest wall [5,6]. Treatment is palliative and symptomatic.erms of the Creative Commons
which permits non-commercial
d theoriginal author and source
o District, Shanghai, China.
First People's Hospital of Lian
lished by Elsevier Inc. All rights reserPresently, there is no effective prevention or disease-altering treatment
[1]. FOP is an autosomal dominant disorder, but the etiology of most
cases is a de novomutationwhich is not inherited frompatient's parents
[7].
FOP is classiﬁed as one of three types based on clinical criteria [7]:
(1) classic FOP — affected individuals have two deﬁning clinical fea-
tures, i.e. characteristic congenital malformations of the great toes
and progressive heterotopic ossiﬁcation in characteristic anatomic
patterns. Additionally, N50% of classic FOP patients have proximal
medial tibial osteochondromas, orthotopic fusions of the cervical verte-
brae, short and broad femoral necks, conductive hearing impairment,
and malformations of the thumbs; (2) FOP-plus — affected individuals
have the classic clinical features of FOP plus one or more atypical fea-
tures. (3) FOP variants — affected individuals have major variations in
one or both of the classic deﬁning features of FOP. In all types of FOP,
the condition can be diagnosed clinically. Genetic studies are conﬁrma-
tory [8].
FOP is caused by heterozygous activating mutations in activin A re-
ceptor, type I/activin-like kinase 2 (ACVR1/ALK2), a bonemorphogenet-
ic protein (BMP) type I receptor, in every individual with FOP [7,10–13].
Approximately 97% of FOP patients worldwide have the classic FOPved.
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ACVR1/ALK2 [11,12]. Approximately 3% of FOP patients have variant
phenotypes and genotypes. The ACVR1/ALK2 R206H mutation and all
of the variants reported exhibit mild constitutive activity and enhanced
ligand-dependent activity of BMP signaling in vitro [7,9–13]. A recently
described knock-in mouse model of the classic FOP mutation recapitu-
lates all of the clinical features of FOP in humans [14,15].
FOP has been reported worldwide. However, in China, the world's
most populous nation, there have been only six well-documented
cases of classic FOP and two FOP variants reported [16–21]. From
2005 to 2012, we prospectively recruited (through Chinese television)
andevaluated 72 individualswith FOP fromChina, and analyzed thenat-
ural history, phenotype, genotype, and radiographic features of these
individuals.
Subjects and research methods
Individual case histories were obtained from patients, parents, or
siblings. There were 72 FOP patients and 98 family controls. Informed
consentwas obtained from all study subjects. All studieswere approved
by the investigational review board of Shanghai Tongji Hospital Afﬁliat-
edwith Tongji University. Patient numbers reﬂect the temporal order in
which they were ﬁrst seen in the clinic for this study.
Medical history, physical examination, and skeletal survey were
obtained on all FOP patients at the time of their ﬁrst clinic visit. Patients
who had clinically apparent ﬂare-ups of FOP in the year prior to the visit
(41 patients) had 99mTc-MDP radionuclide bone scans and serum anal-
ysis for high-sensitivity C-reactive protein (hsCRP) [22].
All study subjects had ACVR1 gene analysis from a peripheral blood
sample obtained after informed consent. ACVR1 gene sequencing and
analysis were performed according to reported protocols [7,9].
Fisher's exact test of Chi-square tests was used to comparemale and
female patient distributions among various onset ages. SPSS13.0 was
used for the statistical analysis.
Results
Epidemiology of FOP
Seventy-two individuals with FOP were evaluated from twenty-ﬁve
provinces of China. No geographical clustering was found. Ninety-nine
percent of patients (71/72 cases) were of Han nationality; and 1% of
patients (1/72 cases) were of Hui nationality, generally reﬂecting theTable 1
Clinical features of classic FOP, FOP-plus, and variant FOP patients.
Classic FOP Atypical featu
Patient code 66 cases 7
ACVR1 mutation
① Codon change R206H R258S
② Nucleotide change c.617GNA c.774GNC
Gender M & F M
Age of HO onset 1 day–14 years 7 years
High resolution karyotype – Normal
Classic FOP features
① Characteristic malformations of great toes Y N
② Progressive HO Y Y
Common variable FOP features
① Perceived conductive hearing impairment 5.6% N
② Cervical spine malformations 48% Y
③ Femoral or tibial osteochondromas 56% Y
④ Short broad femoral necks 68% N
⑤ Thumb malformations 1.5% N
Atypical FOP features N
① Normal or minimal changes in great toes Y
② Childhood glaucoma N
③Marfan's syndrome N
④ Cryptorchidism Ndemography of China. Forty-nine percent of patients (35/72 cases)
were male; and 51% (37/72 cases) were female. The age at the ﬁrst
visit was 18 ± 11 years (mean ± SD) for both males and females; the
age at ﬁrst ﬂare-upwas at least one year earlier and also not signiﬁcant-
ly different between males and females. There was no evidence of FOP
in any of the parents or siblings of FOP patients, indicating that all
cases of FOP were sporadic.
At their initial evaluation, 99% of FOPpatients (71/72 cases) hadmal-
formed great toes with radiographic conﬁrmation. All 72 patients had
decreased range ofmotion of theneck andback and functional ankylosis
of at least three sites including the neck, trunk and an upper limb. All 72
patients had skeletal surveys which showed heterotopic ossiﬁcation in
areas of previous ﬂare-ups.
Patients with classic FOP
According to clinical classiﬁcation schemes for FOP [7], 92% of pa-
tients in our study (66/72 cases) had classic FOP (Table 1). All 66 indi-
viduals had the canonical ACVR1/ALK2 c.617GNA (p.R206H) mutation,
and had both deﬁning clinical features, i.e. characteristic congenital
malformations of the great toes (Fig. 1) and progressive heterotopic
ossiﬁcation. Additionally, some patients had common but variable fea-
tures of FOP including proximalmedial tibial osteochondromas, cervical
spine malformations, and short, broad femoral necks (Fig. 2). Some
common features described in classic FOP, including clinically conductive
hearing impairment and malformations of the thumb [7], were rarely
seen in our patients, but audiology evaluations were not performed
routinely.
Patients with FOP-plus (classic FOP plus atypical clinical features)
Three patients (patients 27, 46, and 70) had FOP-plus (Table 1). All
three patients had the canonical ACVR1/ALK2 c.617GNA (p.R206H)mu-
tation. Each of the three patients had features of classic FOPplus atypical
features that are summarized below:
Patient 27 was diagnosed with FOP at 12 years of age. He was also
diagnosed with Marfan syndrome based on disproportionately long
limbs, arachnodactyly, tall and asthenic body habitus, high-arched pal-
ate, and congenital heart disease, but had no genetic testing for Marfan
syndrome.
Patient 46 injured his right shoulder while playing basketball when
he was 19 years old and rapidly ankylosed his right shoulder. Several
years later he developed spontaneous ﬂare-ups and ankylosis of theres of FOP-plus or FOP variant patients
27 42 46 54 70
R206H R206H R206H G356D R206H
c.617GNA c.617GNA c.617GNA c.1067GNA c.617GNA
M M M F M
12 years 3 years 19 years 3.5 years 6 years
– – – – –
Y N Y Y Y
Y Y Y Y Y
N N N N N
Y N N Y N
Y Y Y N Y
Y Y Y Y Y
N N N Y N
N Y N N N
N N Y N N
Y N N N N
N N N N Y
A2 A1
Fig. 1. Representative appearance of the feet of a patient with classic FOP [ACVR1/ALK2 (R206H)]. A photograph (A1) of the feet of a 6-year-old boy with classic FOP shows bilateral hallux
valgus deformity with the lack of a toe crease at themetatarso-phalangeal joints (arrows) and incidental heterotopic ossiﬁcation of a tendon in the foot (arrowheads). An anterior–posterior
radiograph of the right foot (A2) shows characteristic malformation of the great toe (arrow) with incidental heterotopic bone proximally in a tendon (arrowheads).
388 W. Zhang et al. / Bone 57 (2013) 386–391neck and left shoulder. He also had childhood glaucoma, and was blind
when he came to our clinic at 22 years of age.
Patient 70 had operative correction of cryptorchidism at six years
of age. Post-operatively, he developed soft masses at the operative
site as well as at the site of lumbar puncture for spinal anesthesia.
Later, ﬂare-ups and subsequent ankylosis developed in the back, neck
and both shoulders.
Patients with FOP variants
Three patients were phenotypic variants of FOP (Table 1):
Patient 7, who has previously been reported by our group, had se-
vere digital malformations and a variant mutation in ACVR1/ALK2,
c.774G N C (p.R258S) [21]. Patients with this mutation were also de-
scribed in other nations [23,24].
Patient 42 had normal appearing great toes and thumbs clinically
and radiographically but showed characteristic patterns of postnatal
heterotopic ossiﬁcation. He had the canonical ACVR1/ALK2 c.617GNA
(p.R206H) mutation.
Patient 54 was previously reported by our group [20], and had ini-
tially been classiﬁed as FOP-plus, but she has much more severe
malformations of the toes than the classically affected patients and
is more appropriately considered to be an FOP variant. At 3.5 years
of age, she developed ﬂare-ups and limited motion of her left
shoulder, neck, chest, elbows and hips. She had limited motion in the
interphalangeal joints of both thumbs and both index ﬁngers. She had
a variant mutation in ACVR1/ALK2 at c.1067G N A (p.G356D). This mu-
tation has previously been reported in other FOP variant patients [7,25].
Phenotype–genotype correlation
The R206Hmutationmay cause all three clinical types of FOP includ-
ing classic FOP, FOP-plus and FOP variants. In this large patient series, all
classic FOP and FOP-plus patients and one FOP variant carried the
R206H mutation. Two FOP variant cases had non-R206H mutations.
This phenomenon is consistent with a previous report [7] which only
detected non-R206H mutations in variant FOP patients. None of the 98
unaffected controls, including parents and siblings, had mutations in
ACVR1. Penetrance of the ACVR1/ALK2 mutation was 100%.
Onset of FOP
The parents of the FOP patients could recall the onset and features of
ﬂare-ups in all cases. In this study, the onset of FOPwas considered to bethe time when the ﬁrst spontaneous ﬂare-up appeared or the ﬁrst HO
lesion emerged after trauma.
Spontaneous onset
Sixty-nine percent of patients (50/72 cases) experienced the sponta-
neous onset of ﬂare-ups. Thirty-six percent of patients (18/50 cases) ex-
perienced the spontaneous onset of a ﬂare-up prior to two years of age;
58% of patients (29/50 cases) experienced the spontaneous onset of
a ﬂare-up between two and ten years of age; and 6% of patients (3/50
cases) experienced the spontaneous onset of a ﬂare-up after age 10.
There was no signiﬁcant difference between male and female patient's
distributions among various onset ages (Table 2).
No patient with spontaneous onset of FOP had any premonitory
signs or symptoms prior to the onset of a ﬂare-up. The signs and symp-
toms accompanying the onset of a ﬂare-up were different at different
anatomic sites. If the ﬂare-up was in the head, neck or trunk, the onset
was usually acute with large painless or painful soft masses appearing
within twelve hours. If the ﬂare-up involved the extremities, patients
weremore likely to have had focal pain with decreased range of motion
as their initial complaint, with or without the appearance of soft tissue
swelling.
Fifty-twopercent of patients (26/50 cases)whoexperienced sponta-
neous onset of ﬂare-ups presented with soft tissue swellings in the
occipital region. Typically, as one mass subsided, another one emerged
and sequentially spread toward the back of the neck and trunk. Most
masses eventually ossiﬁed, but some resolved completely. Twenty-
three of the 26 patients who had spontaneous occipital masses had ra-
diographic evidence of HO in the occipital and posterior neck regions
at theﬁrst visit to our clinic, but three of the 26 patientswhohad report-
ed ﬂare-ups in the occipital region had no radiographic evidence of HO
in the occipital region, although these three patients had HO at other
sites where intercurrent ﬂare-ups had occurred.
Forty percent of patients (20/50 cases) with spontaneous onset of
FOP presented with soft tissue swelling or focal edema in the neck,
back, trunk or shoulder, and all of the soft tissue masses become ossi-
ﬁed. Eight percent of patients (4/50 cases) with spontaneous onset of
FOP presented with HO in the hips, knees, or ankles. However, none of
the four patients had any premonitory soft tissue masses or swelling.
One of these four caseswas a patientwho is a phenotypic and genotypic
variant of FOP (patient 7). The other three had classic FOP.
Trauma-induced onset
In 31% of patients (22/72 cases), the initial onset of FOP occurred fol-
lowing trauma. In 18 of the 22 cases, the onset occurred following blunt
AB2B1
DC
E  
Fig. 2.Characteristic and common-variable features of classic FOP [ACVR1/ALK2 (R206H)]. (A) Lateral radiograph of the cervical spine of a 22-year-oldmale FOP patient shows heterotopic
bone in the nuchal ligament (arrow) and posterior orthotopic fusion of the facet joints of several cervical vertebrae (arrowheads). Photograph (B1) and anterior–posterior radiograph (B2)
of the chest of a 16-year-old girl with classic FOP showing subcutaneous bands of heterotopic bone (arrows) in the back. (C) Photograph of the back of a 5-year-old girl with classic FOP
showing twoprominent subcutaneousﬂare-ups (arrows). (D) Anterior–posterior radiographof thepelvis of a 29-year-old femalewith classic FOP showingmature heterotopic ossiﬁcation
bridging the left hip (arrow) and more proximally both the left and right pelvis, as well as intra-articular synovial osteochondromatosis of right hip (arrowheads). The patient also has
characteristic femoral necks that are short and broad. (E) Anterior–posterior radiographs of the knees of a 22-year-old male with classic FOP showing a large sessile osteochondroma
of the left proximal medial tibia and small pedunculated osteochondroma of the right distal femur (arrows). Additionally, there are prominent areas of heterotopic bone in both knees.
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curred after surgical biopsy of an unsuspected FOP lesion. Most of the
parents could not recall the deﬁnitive time interval between the blunt
trauma and the resulting ﬂare-up. Only in six patients was the intervalTable 2
Patient distribution among various onset ages.
b2 years 2–10 years N10 years
Male 10 12 1
Female 8 17 2
Total 18 29 3
p = 0.525 between male and female patients (by Fisher's exact test).clearly remembered by their parents to be one week (three cases), ten
days (one case), two weeks (one case), and three weeks (one case).
The trauma experienced by these 22 patients included blunt trauma
to the occipital region, back of neck, shoulder or elbow, and surgical
procedures for torticollis, congenital hip dysplasia, osteochondroma of
the proximal medial tibia, and fracture of the femoral shaft. In all the
22 patients, spontaneous ﬂare-up would occur subsequent to the
trauma-induced onset.
Progression of FOP
The spatial progression of FOP lesions was similar to that previously
reported [3]. There was no predictable interval between ﬂare-ups for
390 W. Zhang et al. / Bone 57 (2013) 386–391those affected with spontaneous onset or for those who had spontane-
ous ﬂare-ups following an initial post-traumatic ﬂare-up.
Pathological ﬁndings
Eighty-four percent of patients (61/72 cases) were misdiagnosed or
had not been given any diagnosis in local hospitals prior to their visit
to our clinic or our visit to their home. Thirty-six percent of patients
(26/72 cases) had undergone a diagnostic biopsy of an FOP lesion
prior to the deﬁnitive diagnosis of FOP. One hundred percent of those
patients (26/26) developed heterotopic ossiﬁcation at the operative
site as a result of the biopsy. Thepathological ﬁndingswere dramatically
different from patient to patient and reﬂected both the stage of the
lesion at the time of the biopsy and the ignorance of the medical team
regarding the true cause of the pathology. Pathologic misdiagnoses
occurred in 92% of patients (24/26 cases) and included panniculitis,
eosinophilic fasciitis, ﬁbromyoma, nodular fasciitis, benign ﬁbroma, ag-
gressiveﬁbroma, rhabdomyosarcoma, chondroma, osseous fasciitis, and
osteochondroma. 8% of patients (2/26 cases) were correctly diagnosed
with FOP on the basis of the pathologic ﬁndings and the associated toe
malformations. Unfortunately, FOP could have been diagnosed in all
cases on the basis ofmalformed toes and soft tissue swelling and/or het-
erotopic ossiﬁcation before an unnecessary and invasive biopsy had
been performed [4]. Eighty percent of the biopsies (20/26) showed fea-
tures compatible with early to mid-stage FOP lesions that included
degenerated skeletal muscle with inﬂammatory inﬁltrates and early
ﬁbroproliferative tissue without any evidence of cartilage or bone
[23,26,27]. Only three patients were suspected as having FOP by the pa-
thologist on the basis of early cartilage and bone formation. Three addi-
tional biopsies showed mature heterotopic bone, but the patients were
not diagnosed with FOP for unknown reasons.
Radionuclide bone scanning
Radionuclide bone scanning with 99mTc-MDP was performed to de-
termine active or residual foci of heterotopic ossiﬁcation in 41 patients
who had symptoms of FOP ﬂare-ups including focal swelling, pain
and/or decreased range of motion within the year prior to their clinic
visit. Radioisotope uptake indicating mature heterotopic bone was de-
tected at remote sites of previously resolved ﬂare-ups, as expected, in
most individuals. However, if the patient was experiencing symptoms
of an intercurrent ﬂare-up of FOP at the time of the scan (focal pain,
swelling) but heterotopic bone had not yet formed, no radionuclide
uptake was detected. In almost all cases of suspected clinical ﬂare-up,
heterotopic bone eventually formed. In only 3 among 50 cases with
spontaneous onset did the ﬂare-up resolve spontaneously without
forming clinically or radiographically evident heterotopic bone. There-
fore, 99mTc-MDP bone scanning as performed in this FOP patient cohort
was not a sensitive method for diagnosing early FOP ﬂare-ups and was
less accurate than clinical observation.
Laboratory evaluation
Forty-one patients who had an FOP ﬂare-up in the year prior to
their initial evaluation had measurement for serum high-sensitivity
C-reactive protein (hsCRP). Only two patients among the 41 had in-
creased levels of hsCRP which were 12.0 and 27.3 mg/L respectively
(normal: b10 mg/L) [22].
Discussion
China is theworld'smost populous nationwithmore than1.3 billion
people.
Considering the extreme rarity of FOP and the predicted point prev-
alence of approximately 1:2,000,000, one would estimate the existence
of at least 650 patients in China [2]. Until recently, only a few FOPpatients from China had been reported. Here we report 72 patients
with conﬁrmed FOP in China, the largest ethnically homogeneous pop-
ulation of FOP patients in the world. Together with the earlier case re-
ports of six classic FOP patients [16–21], putatively 12% (78/650) of
the population of this disorder in China has been phenotypically and ge-
notypically identiﬁed. Therefore, 88% of the expected FOP patients in
China remain either undiagnosed or unknown to this medical team
and are at risk of lifelong complications frommisdiagnosis unless active
educational programs are instituted to identify patients at risk. The early
diagnosis of FOP can alert doctors and patients alike to avoid diagnostic
misadventures [4,8].
Unfortunately, the misdiagnosis experience for FOP in China is sim-
ilar to that reported elsewhere [4]. Twenty-six of seventy-two patients
had unnecessary diagnostic biopsies of early FOP lesions, all of these at
local hospitals, and were not properly or promptly diagnosed as having
FOP for the same reason that FOP ismisdiagnosed elsewhere. Because of
the rarity of FOP, many physicians in China, as elsewhere, lack experi-
ence in diagnosing FOP and have no prior awareness of the signature
presence of malformed great toes, a harbinger of soft tissue pre-
osseous ﬂare-ups. The diagnosis of FOP is a clinical one and mutational
analysis remains a conﬁrmatory study once the diagnosis is suspected
[1,8]. Our data show that the frequency of FOP variant individuals
from China is similar to that reported elsewhere in the world
[7,9,23,24,26–31], and supports the ﬁdelity of this rare disorder across
wide racial, ethnic, gender and geographic distributions.
FOP lesions mature through an endochondral process [32,33]. Early
pre-chondrogenic ﬂare-ups of FOP are intensely inﬂammatory [34].
Yet, in our patient population there was no consistent marker of sys-
temic inﬂammation. The serum hsCRP levels in 95% of our patients
(39/41 cases) whose FOP had been active at least one year prior to
their evaluation in our clinic were normal. This ﬁnding suggests that
there may be either a lack of generalized inﬂammation in this disease
or a very brief period of systemic inﬂammation that has remain
undetected due to a paucity of studies that examine longitudinal and
stage-speciﬁc biomarkers in this disease. Clearly, there is a need for
such studies. Importantly, we found that radionuclide bone scan was
unhelpful in following the early progression of FOP in our patients. As
with previously reported studies, plain radiographsweremore than suf-
ﬁcient in monitoring the clinical course of the disease [35,36].
Conclusion
In summary, we have reported the clinical and genetic proﬁles of
FOP in China. The results of this study may highlight awareness of this
patient population in the worldwide FOP community, aid in under-
standing worldwide trends in natural history and associated genotype,
serve in identifying a new population for participation in future clinical
trials, and bring critical awareness to the Chinesemedical community so
that prompt and correct clinical diagnosis might ensue and diagnostic
delays might be avoided for the remaining Chinese FOP patients yet to
be diagnosed.
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